Advertisement

Dabigatran Approved for Treatment of Venous Thromboembolism — Physician’s First Watch

Medical News |
April 8, 2014

Dabigatran Approved for Treatment of Venous Thromboembolism

By Larry Husten

The FDA has approved the oral anticoagulant dabigatran (Pradaxa) for the treatment of venous thromboembolism (VTE), the manufacturer announced on Monday.

Dabigatran is now indicated for VTE treatment following therapy with a parenteral anticoagulant for 5 to 10 days. It can also be used to reduce the risk for VTE recurrence in people who've previously been treated.

In 2010, dabigatran was approved for stroke prevention in patients with nonvalvular atrial fibrillation.

Adapted from CardioExchange

Reader Comments (1)

hiba Other Healthcare Professional, Pharmacology/Pharmacy

it was a good article

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement